Impact of ruxolitinib on inflammatory signatures in neutrophils and PBMCs revealed by bulk RNA-seq. (A) Principal component analysis plots of bulk RNA-seq data sets of neutrophils and PBMCs in 3 patients with AOSD-MAS. (B) Volcano plot shows the DEGs in neutrophils and PBMCs with after ruxolitinib and before treatment. Red points represent upregulated genes, blue points represent downregulated genes. (C) Circular bar plot displaying the log2(fold change) of different genes involved in the inflammation response, inflammasome, cytokine, chemokine, IFN-I/II signaling, neutrophil secretion, NETosis, and inflammation regulation after ruxolitinib treatment. (D) Genes and Genomes (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment analysis of DEGs in neutrophils after treatment. (E) GSEA analysis showing the significantly downregulated hallmark gene sets in neutrophils and PBMCs after ruxolitinib treatment. ECM, extracellular matrix; NES, normalized enrichment score.
